Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

ATF2

Introduction

Activating transcription factor 2, also known as ATF2, is a protein that, in humans, is encoded by the ATF2 gene.[1]

Function

Function

This gene encodes a transcription factor that is a member of the leucine zipper family of DNA-binding proteins. This protein binds to the cAMP-responsive element (CRE), an octameric palindrome. The protein forms a homodimer or heterodimer with c-Jun and stimulates CRE-dependent transcription. The protein is also a histone acetyltransferase (HAT) that specifically acetylates histones H2B and H4 in vitro; thus, it may represent a class of sequence-specific factors that activate transcription by direct effects on chromatin components. Additional transcript variants have been identified but their biological validity has not been determined.[1]

The gene atf2 is located at human chromosome 2q32.[2] The protein ATF-2 has 505 amino acids. Studies in mice indicate a role for ATF-2 in the development of nervous system and the skeleton.[3] ATF-2 is normally activated in response to signals that converge on stress-activated protein kinases p38 and JNK.[4] ATF-2 phosphorylation in response to treatment of cells with tumor promoter phorbol ester has been demonstrated.[5]

Several studies implicate abnormal activation of ATF-2 in growth and progression of mammalian skin tumors.[6][7] ATF-2 may mediate oncogenesis caused by mutant Ras protein[8] and regulate maintenance of the aggressive cancer phenotype of some types of epithelial cells. ATF2 has also been shown to be phosphorylated at its C-terminal (Serine 472 and 480 in mouse; Serine 490 and 498 in human) by ATM upon double-stranded breaks. Mice with mutations of these two serines are sensitive to irradiation and easier to tumorigenesis under p53 knockout background.

ATF2 has also been shown to be phosphorylated at its C-terminal (serine 472 and 480 in mouse; serine 490 and 498 in human) by ATM upon double-stranded breaks.[9]

Interactions

Interactions

Activating transcription factor 2 has been shown to interact with

See also

See also

References

References

  1. ↑ 1.0 1.1 “Entrez Gene: ATF2 activating transcription factor 2”.
  2. ↑ Ozawa K, Sudo T, Soeda E, Yoshida MC, Ishii S (1991). “Assignment of the human CREB2 (CRE-BP1) gene to 2q32”. Genomics. 10 (4): 1103–4. doi:10.1016/0888-7543(91)90210-6. PMIDΒ 1833307.
  3. ↑ Reimold AM, Grusby MJ, Kosaras B, Fries JW, Mori R, Maniwa S, Clauss IM, Collins T, Sidman RL, Glimcher MJ, Glimcher LH (1996). “Chondrodysplasia and neurological abnormalities in ATF-2-deficient mice”. Nature. 379 (6562): 262–5. doi:10.1038/379262a0. PMIDΒ 8538792.
  4. ↑ Gupta S, Campbell D, DΓ©rijard B, Davis RJ (1995). “Transcription factor ATF2 regulation by the JNK signal transduction pathway”. Science. 267 (5196): 389–93. doi:10.1126/science.7824938. PMIDΒ 7824938.
  5. ↑ Yamasaki T, Takahashi A, Pan J, Yamaguchi N, Yokoyama KK (March 2009). “Phosphorylation of Activation Transcription Factor-2 at Serine 121 by Protein Kinase C Controls c-Jun-mediated Activation of Transcription”. J. Biol. Chem. 284 (13): 8567–81. doi:10.1074/jbc.M808719200. PMCΒ 2659215. PMIDΒ 19176525.
  6. ↑ Leslie MC, Bar-Eli M (2005). “Regulation of gene expression in melanoma: new approaches for treatment”. J. Cell. Biochem. 94 (1): 25–38. doi:10.1002/jcb.20296. PMIDΒ 15523674.
  7. ↑ Papassava P, Gorgoulis VG, Papaevangeliou D, Vlahopoulos S, van Dam H, Zoumpourlis V (2004). “Overexpression of activating transcription factor-2 is required for tumor growth and progression in mouse skin tumors”. Cancer Res. 64 (23): 8573–84. doi:10.1158/0008-5472.CAN-03-0955. PMIDΒ 15574764.
  8. ↑ Vlahopoulos SA, Logotheti S, Mikas D, Giarika A, Gorgoulis V, Zoumpourlis V (17 March 2008). “The role of ATF-2 in oncogenesis”. BioEssays. 30 (4): 314–27. doi:10.1002/bies.20734. PMIDΒ 18348191.
  9. ↑ Bhoumik A, Takahashi S, Breitweiser W, Shiloh Y, Jones N, Ronai Z (May 2005). “ATM-dependent phosphorylation of ATF2 is required for the DNA damage response”. Mol. Cell. 18 (5): 577–87. doi:10.1016/j.molcel.2005.04.015. PMCΒ 2954254. PMIDΒ 15916964.
  10. ↑ Newell CL, Deisseroth AB, Lopez-Berestein G (July 1994). “Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene”. J. Leukoc. Biol. 56 (1): 27–35. PMIDΒ 8027667.
  11. ↑ Kara CJ, Liou HC, Ivashkiv LB, Glimcher LH (April 1990). “A cDNA for a human cyclic AMP response element-binding protein which is distinct from CREB and expressed preferentially in brain”. Mol. Cell. Biol. 10 (4): 1347–57. PMCΒ 362236. PMIDΒ 2320002.
  12. ↑ Hai T, Curran T (May 1991). “Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity”. Proc. Natl. Acad. Sci. U.S.A. 88 (9): 3720–4. doi:10.1073/pnas.88.9.3720. PMCΒ 51524. PMIDΒ 1827203.
  13. ↑ 13.0 13.1 Yamaguchi Y, Wada T, Suzuki F, Takagi T, Hasegawa J, Handa H (August 1998). “Casein kinase II interacts with the bZIP domains of several transcription factors”. Nucleic Acids Res. 26 (16): 3854–61. doi:10.1093/nar/26.16.3854. PMCΒ 147779. PMIDΒ 9685505.
  14. ↑ Sano Y, Tokitou F, Dai P, Maekawa T, Yamamoto T, Ishii S (October 1998). “CBP alleviates the intramolecular inhibition of ATF-2 function”. J. Biol. Chem. 273 (44): 29098–105. doi:10.1074/jbc.273.44.29098. PMIDΒ 9786917.
  15. ↑ Murata T, Shinozuka Y, Obata Y, Yokoyama KK (May 2008). “Phosphorylation of two eukaryotic transcription factors, Jun dimerization protein 2 and activation transcription factor 2, in Escherichia coli by Jun N-terminal kinase 1”. Anal. Biochem. 376 (1): 115–21. doi:10.1016/j.ab.2008.01.038. PMIDΒ 18307971.
  16. ↑ 16.0 16.1 Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ (March 1995). “Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine”. J. Biol. Chem. 270 (13): 7420–6. doi:10.1074/jbc.270.13.7420. PMIDΒ 7535770.
  17. ↑ 17.0 17.1 Chen Z, Cobb MH (May 2001). “Regulation of stress-responsive mitogen-activated protein (MAP) kinase pathways by TAO2”. J. Biol. Chem. 276 (19): 16070–5. doi:10.1074/jbc.M100681200. PMIDΒ 11279118.
  18. ↑ 18.0 18.1 Tournier C, Whitmarsh AJ, Cavanagh J, Barrett T, Davis RJ (July 1997). “Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase”. Proc. Natl. Acad. Sci. U.S.A. 94 (14): 7337–42. doi:10.1073/pnas.94.14.7337. PMCΒ 23822. PMIDΒ 9207092.
  19. ↑ Fuchs SY, Xie B, Adler V, Fried VA, Davis RJ, Ronai Z (December 1997). “c-Jun NH2-terminal kinases target the ubiquitination of their associated transcription factors”. J. Biol. Chem. 272 (51): 32163–8. doi:10.1074/jbc.272.51.32163. PMIDΒ 9405416.
  20. ↑ Sano Y, Harada J, Tashiro S, Gotoh-Mandeville R, Maekawa T, Ishii S (March 1999). “ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling”. J. Biol. Chem. 274 (13): 8949–57. doi:10.1074/jbc.274.13.8949. PMIDΒ 10085140.
  21. ↑ Hong S, Choi HM, Park MJ, Kim YH, Choi YH, Kim HH, Choi YH, Cheong J (April 2004). “Activation and interaction of ATF2 with the coactivator ASC-2 are responsive for granulocytic differentiation by retinoic acid”. J. Biol. Chem. 279 (17): 16996–7003. doi:10.1074/jbc.M311752200. PMIDΒ 14734562.
  22. ↑ Cho SG, Bhoumik A, Broday L, Ivanov V, Rosenstein B, Ronai Z (December 2001). “TIP49b, a regulator of activating transcription factor 2 response to stress and DNA damage”. Mol. Cell. Biol. 21 (24): 8398–413. doi:10.1128/MCB.21.24.8398-8413.2001. PMCΒ 100004. PMIDΒ 11713276.
  23. ↑ Firestein R, Feuerstein N (March 1998). “Association of activating transcription factor 2 (ATF2) with the ubiquitin-conjugating enzyme hUBC9. Implication of the ubiquitin/proteasome pathway in regulation of ATF2 in T cells”. J. Biol. Chem. 273 (10): 5892–902. doi:10.1074/jbc.273.10.5892. PMIDΒ 9488727.
External links
Further reading

Further reading